Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Breast Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 47 articles: HTML format

Single Articles

May 2025
1. DAUCCIA C, Alice Franzoi M, Martel S, Agbor-Tarh D, et al
   Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
   Eur J Cancer. 2025;223:115489.
   PubMed     Abstract available
   
   
   
2. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
   Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
   Eur J Cancer. 2025;220:115377.
   PubMed     Abstract available
   
   
   April 2025
3. DING N, Hermans KEPE, van Nijnatten TJA, Engelen SME, et al
   Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients.
   Eur J Cancer. 2025;222:115475.
   PubMed     Abstract available
   
   
   
4. BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al
   Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
   Eur J Cancer. 2025;222:115438.
   PubMed     Abstract available
   
   
   
5. MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al
   Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
   Eur J Cancer. 2025;222:115434.
   PubMed     Abstract available
   
   
   
6. DE PLACIDO P, Di Rienzo R, Pietroluongo E, Martinelli C, et al
   Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.
   Eur J Cancer. 2025;221:115409.
   PubMed     Abstract available
   
   
   
7. MIYAWAKI IA, Banerjee I, Batalini F, Campello Jorge CA, et al
   Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity.
   Eur J Cancer. 2025;220:115394.
   PubMed     Abstract available
   
   
   March 2025
8. BEDARD PL, Jhaveri KL, Accordino MK, Cervantes PA, et al
   Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
   Eur J Cancer. 2025;221:115397.
   PubMed     Abstract available
   
   
   
9. BOTTOSSO M, Sandoval RL, Verret B, Polidorio N, et al
   Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].
   Eur J Cancer. 2025 Mar 18:115370. doi: 10.1016/j.ejca.2025.115370.
   PubMed    
   
   
   
10. SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al
    Update of the impact of menopausal hormone therapy on breast cancer risk.
    Eur J Cancer. 2025;220:115340.
    PubMed     Abstract available
    
    
    February 2025
11. METZGER FILHO O, Cardoso F, Poncet C, Desmedt C, et al
    Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.
    Eur J Cancer. 2025;217:115222.
    PubMed     Abstract available
    
    
    
12. GRIGUOLO G, Bottosso M, Crema A, Giarratano T, et al
    Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes.
    Eur J Cancer. 2025;219:115321.
    PubMed     Abstract available
    
    
    
13. STEGER K, Fiegl H, Feroz B, Leitner K, et al
    Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
    Eur J Cancer. 2025;219:115320.
    PubMed     Abstract available
    
    
    January 2025
14. COTTU P
    Identifying and managing adverse prognosis biomarkers among advanced luminal breast cancer patients: What have we learned?
    Eur J Cancer. 2025 Jan 10:115228. doi: 10.1016/j.ejca.2025.115228.
    PubMed    
    
    
    
15. HART LL, Im SA, Tolaney SM, Campone M, et al
    Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
    Eur J Cancer. 2025;217:115225.
    PubMed     Abstract available
    
    
    
16. GIL QUESSEP E, van der Waal D, Peters J, Delaloge S, et al
    Subgroups varying in risk and density highlight the potential for stratified breast cancer screening.
    Eur J Cancer. 2025;217:115220.
    PubMed     Abstract available
    
    
    
17. TOLOSA P, Pascual T, Martinez-Saez O, Hernando C, et al
    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.
    Eur J Cancer. 2025 Jan 3:115219. doi: 10.1016/j.ejca.2024.115219.
    PubMed     Abstract available
    
    
    December 2024
18. DENNIS N, Dunton K, Livings C, Bogoeva N, et al
    Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
    Eur J Cancer. 2024;217:115192.
    PubMed     Abstract available
    
    
    
19. NEVEN P, Han S, Verhoeven D, Soubry A, et al
    Letter re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024 Dec 14:115166. doi: 10.1016/j.ejca.2024.115166.
    PubMed    
    
    
    
20. LEROY R, Bourgeois J, Canon JL, Carly B, et al
    Response to letter entitled: Re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024 Dec 9:115167. doi: 10.1016/j.ejca.2024.115167.
    PubMed    
    
    
    
21. MILANO M, Valenza C, Ferrari A, Gandini S, et al
    Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.
    Eur J Cancer. 2024;215:115164.
    PubMed     Abstract available
    
    
    November 2024
22. MOLINELLI C, Bruzzone M, Blondeaux E, Ruelle T, et al
    The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
    Eur J Cancer. 2024;213:115113.
    PubMed     Abstract available
    
    
    
23. ANKERSMID JW, Drossaert CHC, Strobbe LJA, Hackert MQN, et al
    Shared decision-making supported by outcome information regarding surveillance after curative treatment for breast cancer: Results of the SHOUT-BC study.
    Eur J Cancer. 2024;213:115107.
    PubMed     Abstract available
    
    
    October 2024
24. LIVRAGHI L, Martella F, Ghilli M, Angiolini C, et al
    Prospective study on Oncotype DX(R) assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
    Eur J Cancer. 2024;213:115108.
    PubMed     Abstract available
    
    
    
25. VALENZA C, Trapani D, Zagami P, Antonarelli G, et al
    Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
    Eur J Cancer. 2024;213:115097.
    PubMed     Abstract available
    
    
    
26. ANTOINE A, Perol D, Robain M, Bachelot T, et al
    Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation.
    Eur J Cancer. 2024;213:115072.
    PubMed     Abstract available
    
    
    
27. LEE DW, Ryu HS, Nikas IP, Koh J, et al
    Immune marker expression and prognosis of early breast cancer expressing HER3.
    Eur J Cancer. 2024;213:115081.
    PubMed     Abstract available
    
    
    
28. VAN OMMEN-NIJHOF A, Steenbruggen TG, Wiersma TG, Balduzzi S, et al
    Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
    Eur J Cancer. 2024;213:115083.
    PubMed     Abstract available
    
    
    September 2024
29. GANNON MR, Dodwell D, Miller K, Medina J, et al
    Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data.
    Eur J Cancer. 2024;211:114309.
    PubMed     Abstract available
    
    
    
30. BOTTOSSO M, Sandoval RL, Verret B, Polidorio N, et al
    HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome.
    Eur J Cancer. 2024;211:114307.
    PubMed     Abstract available
    
    
    
31. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    PubMed     Abstract available
    
    
    
32. CHEN J, Yin Y, Li G, Tian H, et al
    Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches.
    Eur J Cancer. 2024;209:114259.
    PubMed     Abstract available
    
    
    August 2024
33. STEVENTON L, Kipps E, Man KK, Roylance R, et al
    The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.
    Eur J Cancer. 2024;210:114301.
    PubMed     Abstract available
    
    
    
34. DUBOEUF M, Amadou A, Coudon T, Grassot L, et al
    Long-term exposure to air pollution at residential and workplace addresses and breast cancer risk: A case-control study nested in the French E3N-Generations cohort from 1990 to 2011.
    Eur J Cancer. 2024;210:114293.
    PubMed     Abstract available
    
    
    July 2024
35. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    PubMed     Abstract available
    
    
    
36. LEROY R, Silversmit G, Bourgeois J, De Gendt C, et al
    Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024;210:114232.
    PubMed     Abstract available
    
    
    
37. DARBANDI MR, Darbandi M, Darbandi S, Bado I, et al
    Artificial intelligence breakthroughs in pioneering early diagnosis and precision treatment of breast cancer: A multimethod study.
    Eur J Cancer. 2024;209:114227.
    PubMed     Abstract available
    
    
    
38. MARTINS-BRANCO D, Nader-Marta G, Molinelli C, Ameye L, et al
    Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
    Eur J Cancer. 2024;208:114195.
    PubMed    
    
    
    June 2024
39. HASLAM A, Ranganathan S, Prasad V, Olivier T, et al
    CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms.
    Eur J Cancer. 2024;207:114192.
    PubMed     Abstract available
    
    
    
40. CHEW SM, Ferraro E, Safonov A, Chen Y, et al
    Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Eur J Cancer. 2024;207:114175.
    PubMed     Abstract available
    
    
    
41. IGNATIADIS M, Poulakaki F, Spanic T, Brain E, et al
    EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.
    Eur J Cancer. 2024;207:114156.
    PubMed     Abstract available
    
    
    May 2024
42. HAN W, Zhang DD, Zhang YW, Shi LZ, et al
    Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2024 May 22:114126. doi: 10.1016/j.ejca.2024.114126.
    PubMed    
    
    
    April 2024
43. GUERINI-ROCCO E, Bellerba F, Concardi A, Taormina SV, et al
    Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
    Eur J Cancer. 2024;203:114063.
    PubMed     Abstract available
    
    
    
44. COLOMBO I, Koster KL, Holer L, Haefliger S, et al
    TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
    Eur J Cancer. 2024;201:113588.
    PubMed     Abstract available
    
    
    
45. BARTELS SAL, van Olmen JP, Scholten AN, Bekers EM, et al
    Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 -2020).
    Eur J Cancer. 2024;201:113924.
    PubMed     Abstract available
    
    
    March 2024
46. ROUSSOT N, Constantin G, Desmoulins I, Bergeron A, et al
    Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2024;202:114037.
    PubMed     Abstract available
    
    
    
47. UNTCH M, Perol D, Mayer EL, Cortes J, et al
    Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Eur J Cancer. 2024;202:113977.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.